Zealand Pharma A/S (ZEAL) 2017年年度报告「NASDAQ」.pdf

1、Accelerating the late-stage clinical pipelineZealand Pharma Annual Report 2017Company reg.no.20045078Marianne Riislives with short bowel syndrome and is dependent on parenteral nutrition.Our ambition is to be a worldleader in treating specialty gastrointestinal and metabolic diseasesAt Zealand,we ar

2、e passionate about improving patients lives and committed to delivering value for all our stakeholders.2Zealand Pharma Annual Report 20172Zealand Pharma Annual Report 2017About Zealand PharmaMoving forwardProducts and pipelineCorporate mattersFinancial statementsOther informationContentsAbout Zealan

3、d PharmaZealand in brief 5Chairmans letter 6CEO letter 7Financial highlights and 2018guidance 9Consolidated key figures 10Zealands IPO on Nasdaq in the U.S.11Key events 2017 12Zealands pipeline 13Products and pipelineMarketed products 23Marianne Riis,SBS patient 24Glepaglutide for SBS 26Dasiglucagon

4、 for congenital hyperinsulinism 27Dasiglucagon for severe hypoglycemia 28Dasiglucagon for use in a dual-hormone pump 29Two obesity programs:amylin analog and GLP-1/GLU 30Research and preclinical projects 31Moving forwardOur ambition and priorities for 2018 15Zealands business model 16A dual-listed c

5、ompany 17Late-stage development organization 18Zealands scientific peptide platform 19Toward an integrated biotech company 20Working with partners 21Corporate mattersCorporate governance 33Risk management and internal control 36Corporate social responsibility(CSR)39Human resources 40Financial review

6、 41Shareholder information 44Board of Directors and Corporate Management 46Other informationSources 95Addresses(company information)95CEO letter2017 was a defining year for Zealand,with transformational progress across the business.Read more onpage 7Late-stage pipelineZealand aspires to become a wor